Hims & Hers shares rise 8.1% on Eli Lilly obesity drug deal
The gist
Telehealth firm Hims & Hers rose 8.1% to $26.00 after announcing an Eli Lilly obesity drug deal.
The stock is down 40.5% over a year, with Q3 earnings due Nov 9.
How it unfolded
- Feb 27, 2026HIMS set its 52-week closing low of $14.52.
- Aug 10, 2026Management said on its Q2 FY2026 call it was thrilled with the strength of its Novo Nordisk relationship; from that day to Nov 6 the stock fell 18.2% while the S&P 500 lost 4.6%.
- Nov 4, 2026Argus lowered its HIMS target price to $24.00, with the price then cited at $26.66.
Key terms
- telehealth
- Use of electronic information and telecommunication technologies to support long-distance clinical health care, education, and health administration.
- compounded versions
- Custom-made medications prepared by a pharmacy to fit a specific prescription rather than mass-produced formulations.
- short interest
- The number of shares sold short by investors, often expressed relative to average daily trading volume.
Source: Wikipedia